Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
THG strikes deal with Greencore to sell protein-enriched convenience foods
(Sharecast News) - THG is to target the booming obesity jab market through a strategic partnership with convenience food producer Greencore Group, it confirmed on Thursday. Under the terms of the deal, financial details of which were not disclosed, Greencore will produce a range of on-the-go convenience foods, including salads and wraps, under THG's Myprotein sports nutrition brand.
The range will be sold in Sainsbury's supermarkets and convenience stores.
Neil Mistry, chief executive of THG Nutrition, said: "The range builds on the demand of GLP-1 consumers, along with trends towards cleaner nutrition combined with protein-rich foods and snacks.
"This partnership not only widens the reach of the Myprotein brand offering, it brings further significant penetration into offline channels."
Andy Parton, Greencore's chief commercial officer, said: "As demand grows for convenient, nutritious products that support healthier lifestyles, this collaboration allows us to combine Greencore's expertise...with one of the most recognisable brands in sports nutrition."
Used for the treatment of both diabetes and obesity, demand for GLP-1 drugs such as Ozempic and Mounjaro has boomed in recent years. UBS currently expects sales to reach $130bn by the end of the decade, with around 52m patients taking a GLP-1 in 2030, up from 13m in 2024.
Users are advised to increase protein intake, to help prevent muscle loss during rapid weight loss.
The Greencore partnership is the latest in a number of licensing agreements struck by THG for its nutrition brands, including Muller, Iceland and Jimmy's Coffee. It is targeting selling-in over 60m licensed products this year, up from 43m in 2025.
As at 0900 GMT, Greencore was down 5% at 279.25p, while THG was 2% higher at 36.08p.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.